Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer

BACKGROUND: Invariant natural killer T (iNKT) cells produce copious amounts of cytokines in response to specific glycolipid antigens such as α-galactosylceramide (αGalCer) presented by CD1d-expressing antigen-presenting cells (APCs), thus orchestrating other immune cells to fight tumors. Because of...

Descripción completa

Detalles Bibliográficos
Autores principales: Toyoda, Takahide, Kamata, Toshiko, Tanaka, Kazuhisa, Ihara, Fumie, Takami, Mariko, Suzuki, Hidemi, Nakajima, Takahiro, Ikeuchi, Takayuki, Kawasaki, Yohei, Hanaoka, Hideki, Nakayama, Toshinori, Yoshino, Ichiro, Motohashi, Shinichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078938/
https://www.ncbi.nlm.nih.gov/pubmed/32188702
http://dx.doi.org/10.1136/jitc-2019-000316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078938/
https://www.ncbi.nlm.nih.gov/pubmed/32188702
http://dx.doi.org/10.1136/jitc-2019-000316

Ejemplares similares